PT -期刊文章盟Giacomo Boffa AU -安德里亚Tacchino AU -埃尔韦拉Sbragia AU -西蒙娜Schiavi AU - Amgad Droby AU -尼科洛比亚乔盟会Bommarito AU -盖亚吉拉迪盟Giovanni Luigi Mancardi盟Giampaolo Brichetto盟——马蒂尔德Inglese TI -保存大脑功能可塑性在上肢面向任务的康复进展型多发性硬化症(S33.002) DP - 2019年4月09年TA -神经病学PG - S33.002 VI - 92 IP - 15补充4099 - //www.ez-admanager.com/content/92/15_Supplement/S33.002.short 4100 - //www.ez-admanager.com/content/92/15_Supplement/S33.002.ful首页l所以Neurology2019 4月09年;92 AB -目的:调查任务导向的影响上肢(UL)康复进展型多发性硬化症(PMS)和评估MRI电动机性能的变化相关。背景:尽管UL功能障碍的临床相关性,有限的研究一直致力于UL康复在经前综合症,导致缺乏循证指南。因此仍未知是否更多的患者禁用高级项目经理仍能受益于运动康复。设计/方法:35 PMS患者前瞻性,随机分为3组:积极治疗组(ATG, n = 13),被动治疗组(PTG, n = 13)和对照组(CG, n = 9)。在基线和训练后,病人接受了核磁共振扫描和与行动研究机构进行评估测试(ARAT)、九孔挂钩测试(9-HPT) ABILHAND规模,修改后的疲劳影响规模(小额信贷机构)。电动机的手指性能指标也得到工程手套测量。结果:康复后,ATG改善在几个UL电动机任务≤0.02 (p≤0.03),显示增加ABILHAND分数相比PTG(术中,0.01)。ATG显示增加的感觉运动功能连通性和丘脑的静息状态的网络相比,CG和PTG(术中;0.05 cluster-wise-FDR-corrected)。运动改善和丘脑之间的相关性被发现,感觉运动和基底神经节网络(0.70 r≤≤0.79, 0.008≤p≤0.04)。未发现结构的MRI改变以DTI。Conclusions: PMS patients could benefit from task-oriented UL rehabilitation, which seems to be more efficient than passive mobilization. Despite extensive brain damage, functional neuroplasticity seems to be preserved in PMS, thus providing a rationale for the use of rehabilitative treatments in late PMS.Disclosure: Dr. Boffa has nothing to disclose. Dr. Tacchino has nothing to disclose. Dr. Sbragia has nothing to disclose. Dr. Schiavi has nothing to disclose. Dr. Droby has nothing to disclose. Dr. Piaggio has nothing to disclose. Dr. Bommarito has nothing to disclose. Dr. Girardi has nothing to disclose. Dr. Mancardi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer Schering, Biogen Idec, Sanofi Aventis, Teva, Genzyme and Merck Serono Pharmaceuticals. Dr. Brichetto has nothing to disclose. Dr. Inglese has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dr. Inglese reports grants from Novartis Pharmaceuticals, National Multiple Sclerosis Society, Noto Foundation, NIH and Teva Neuroscience.